Our mission is to improve DRC tools

Our mission is to improve DRC tools

ThermoCap Laboratories is developing the next generation of Differential Scanning Calorimetry (DSC) technologies.

Our mission is to improve DSC tools

At ThermoCap, we're committed to advancing calorimetry technology to meet the evolving needs of drug discovery and biological research.

At ThermoCap Laboratories, we are revolutionizing the collection and interpretation of DSC data. Our proprietary, next generation DSC technology is called Direct Ratiometric Calorimetry (DRC) and our tools are tailor-made to improve drug discovery and screening.

Drug Screening Analysis: The ThermoCap platform employs DRC thermal analysis of proteins to evaluate drug binding. Our ratiometric method is extremely user-friendly and simple. It provides quantitative evaluation of both binding constants and binding stoichiometry of drug interactions to the target protein.

An additional advantage of our technology is our novel sample preparation methodology for testing and analysis of poor or insoluble drugs. Our protein-mediated process requires minimum amounts of drugs (milligrams) while avoiding the necessity (for solubility purposes) of organic solvents in drug/protein solutions. 

Expression System Analysis: We have developed a unique DRC method utilizing DNA probes for determining unknown concentrations of biological molecules in both pure and impure solutions. Our probes are universally applicable to a wide range of biological molecules and enable mass quantification prior to purification. This advance allows for initial analysis of biologics early in the production process, lowering associated time requirements and resource costs.

RapiDRC: The RapiDRC is a calorimetry instrument currently in development at ThermoCap Labs and is specially designed to empower Direct Ratiometric Calorimetry processes. The RapiDRC is capable of processing 24-96 samples in parallel, using a single bench-top instrument. The speed and capabilities offered by this instrument will be a leap forward for applying calorimetry to drug discovery and health screening applications.

At ThermoCap Laboratories, we are revolutionizing the collection and interpretation of DSC data. Our proprietary, next generation DSC technology is called Direct Ratiometric Calorimetry (DRC) and our tools are tailor-made to improve drug discovery and screening.

Drug Screening Analysis: The ThermoCap platform employs DRC thermal analysis of proteins to evaluate drug binding. Our ratiometric method is extremely user-friendly and simple. It provides quantitative evaluation of both binding constants and binding stoichiometry of drug interactions to the target protein.

An additional advantage of our technology is our novel sample preparation methodology for testing and analysis of poor or insoluble drugs. Our protein-mediated process requires minimum amounts of drugs (milligrams) while avoiding the necessity (for solubility purposes) of organic solvents in drug/protein solutions. 

Expression System Analysis: We have developed a unique DRC method utilizing DNA probes for determining unknown concentrations of biological molecules in both pure and impure solutions. Our probes are universally applicable to a wide range of biological molecules and enable mass quantification prior to purification. This advance allows for initial analysis of biologics early in the production process, lowering associated time requirements and resource costs.

RapiDRC: The RapiDRC is a calorimetry instrument currently in development at ThermoCap Labs and is specially designed to empower Direct Ratiometric Calorimetry processes. The RapiDRC is capable of processing 24-96 samples in parallel, using a single bench-top instrument. The speed and capabilities offered by this instrument will be a leap forward for applying calorimetry to drug discovery and health screening applications.

At ThermoCap Laboratories, we are revolutionizing the collection and interpretation of DSC data. Our proprietary, next generation DSC technology is called Direct Ratiometric Calorimetry (DRC) and our tools are tailor-made to improve drug discovery and screening.

Drug Screening Analysis: The ThermoCap platform employs DRC thermal analysis of proteins to evaluate drug binding. Our ratiometric method is extremely user-friendly and simple. It provides quantitative evaluation of both binding constants and binding stoichiometry of drug interactions to the target protein.

An additional advantage of our technology is our novel sample preparation methodology for testing and analysis of poor or insoluble drugs. Our protein-mediated process requires minimum amounts of drugs (milligrams) while avoiding the necessity (for solubility purposes) of organic solvents in drug/protein solutions. 

Expression System Analysis: We have developed a unique DRC method utilizing DNA probes for determining unknown concentrations of biological molecules in both pure and impure solutions. Our probes are universally applicable to a wide range of biological molecules and enable mass quantification prior to purification. This advance allows for initial analysis of biologics early in the production process, lowering associated time requirements and resource costs.

RapiDRC: The RapiDRC is a calorimetry instrument currently in development at ThermoCap Labs and is specially designed to empower Direct Ratiometric Calorimetry processes. The RapiDRC is capable of processing 24-96 samples in parallel, using a single bench-top instrument. The speed and capabilities offered by this instrument will be a leap forward for applying calorimetry to drug discovery and health screening applications.

Leadership

Leadership

Leadership

Matthew W. Eskew, PhD

Co-Founder & CEO

Matthew W. Eskew, Ph.D. is the CEO and co-founder of ThermoCap Laboratories.  Since 2020 he has served multiple roles in research and development of the Company’s core technologies. Through his academic training in engineering and biological sciences he has acquired a diverse set of skills in computer programming, data analysis, engineering design, and prototyping.  Matt brings a “big picture” view of the business and technological challenges and issues facing the company, while having a deep understanding of the scientific basis of the technology.

Albert S. Benight, PhD

Co-Founder & Chief Scientific Officer

Dr. Benight is the CSO and co-founder of ThermoCap Laboratories. He has spent over 35-years of his career conducting basic research and straddling the line between academic and business-related endeavors. His academic background is in biophysical chemistry of biological macromolecules (particularly DNA and proteins), high-throughput molecular diagnostics, and biomarker discovery.  He has founded several start-ups, most notedly Tm Bioscience, acquired by Luminex in 2006.  Tm developed the first DNA microarray-based genetic test to get FDA approval.

Stay up to date on company news & events

Our products and techology are in development. Sign up here and we will periodically keep you updated on our progress.

Stay up to date on company news & events

Our products and techology are in development. Sign up here and we will periodically keep you updated on our progress.

Stay up to date on company news & events

Our products and techology are in development. Sign up here and we will periodically keep you updated on our progress.